

Ref: FOIA Reference 2019/20-021

Royal Stoke University Hospital

Quality, Safety and Compliance Department Newcastle Road Stoke-on-Trent Staffordshire ST4 6QG

Date: 17<sup>th</sup> April 2019

Email foi@uhnm.nhs.uk

Dear

I am writing in response to your email dated 9<sup>th</sup> April 2019 requesting information under the Freedom of Information Act (2000) regarding drug usage.

As of 1<sup>st</sup> November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

## Q1 Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Kidney Carcinoma (Renal Cell – RCC);

If you do not treat, where do yo	ou refer these patients?
----------------------------------	--------------------------

Drug Name	Patient Totals
Axinitib	
Cabozantinib	
Everolimus	
Levantinib +	
Everolimus	
Nivolumab	
Nivolumab +	
Ipilimumab	
Pazopanib	
Sunitinib	
Temsirolimus	
Tivozanib	

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

ie, please see beletin	
Drug Name	Patient
	Totals







Axitinib	Less than 5
Cabozantinib	5
Everolimus	Less than 5
Lenvatinib +	0
Everolimus	
Nivolumab	7
Nivolumab +	0
Ipilimumab	
Pazopanib	11
Sunitinib	10
Temsirolimus	0
Tivozanib	Less than 5

Q2 Within your Health Trust how many patients are currently (within the past 3 months) being treated with the following treatments for Melanoma?

Drug Name Patients?	
Drug Name	
	Totals
Bevacizumab	
Dabrafenib	
Dabrafenib +	
Trametinib	
Dacarbazine (DTIC)	
Densoumab	
Encorafenib with	
Binimetinib	
lpilumumb	
Nivolumab	
Nivolumab +	
lpilumumb	
Pembrolizumab	
Trametinib	
Vemurafenib	
Vemurafenib +	
Cobimetinib	

If you do not treat, where do you refer these patients?

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers, please see below:

Drug Name	Patient
	Totals





## University Hospitals of North Midlands NHS Trust

Bevacizumab	0
Dabrafenib	0
Dabrafenib +	15
Trametinib	
Dacarbazine (DTIC)	0
Denosumab	5
Encorafenib with	0
Binimetinib	
Ipilimumab	Less than
	5
Nivolumab	Less than
	5
Nivolumab +	Less than
Ipilimumab	5
Pembrolizumab	11
Trametinib	0
Vemurafenib	0
Vemurafenib +	0
Cobimetinib	

## Q3 In the past 3 months, how many Melanoma patients was BRAF+?

A3 Information not held by UHNM as the BRAF testing is sent to an external laboratory. Our cases sent to Queen Elizabeth Hospital Birmingham for testing. Further information may be available by contacting them at the following email: <u>FOI.UHB@uhb.nhs.uk</u>)

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

## UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <a href="http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/">http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/</a>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <u>http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx</u>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.







Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via <u>www.ico.org.uk</u>.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,

L Carlisle

Leah Carlisle Deputy Head of Quality, Safety & Compliance



